SUBMISSIONS to the Pharmaceutical Benefits Advisory Committee in relation to a new migraine prevention treatment called Aimovig (erenumab) are due by close of business today.
If the PBAC decides in favour of the medication it could become affordable for the millions of people suffering from migraine when it is released in Australia later in 2018.
See headacheaustralia.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jun 18
